by Marisa Wexler, MS | Jan 22, 2026 | Myeloma News
Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial. New imaging data confirm that the radioactive therapy effectively targeted and bound to high-grade gliomas,...
by Marisa Wexler, MS | Jan 21, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior...
by Marisa Wexler, MS | Jan 20, 2026 | Myeloma News
Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase 3 clinical trial, according to top-line results announced by the therapy’s developer,...
by MM360 Staff | Jan 17, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jan 17, 2026 | Uncategorized
Source: CURE articles Post Content Read More
